- Conditions
- End Stage Renal Disease, Hepatitis C
- Interventions
- 300mg glecaprevir/pibrentasivir 120mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced May 21, 2026, 8:15 PM EDT